Week in review: sNDA for tapinarof cream 1%, psychological interventions for asthma
Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.
Image credit: Contemporary Pediatrics
Thank you for visiting the Contemporary Pediatrics® website. Take a look at some of our top stories from last week (Monday, February 12 to Friday, February 16, 2024), and click on each link to read and watch anything you may have missed.
1.) Dermavant submits sNDA for tapinarof cream, 1% to treat AD in patients 2 years and up
The sNDA submission follows additional positive topline data that was presented in Janurary 2024, highlighting an open-label, long-term extension study evaluating tapinarof cream, 1%.
Click here for the full article.
2.) Reaction to tapinarof cream, 1% sNDA submission with Lawrence Eichenfield, MD
Lawrence Eichenfield, MD, highlights the sNDA submission of tapinarof cream, 1% for the topical treatment of atopic dermatitis in children aged 2 years and older.
Click here for the full Q+A transcript.
3.) Psychological interventions for asthma and stress reduction
Discover how recent research unveils the potential of psychological interventions in alleviating asthma attacks and mitigating associated psychological stressors, shedding light on promising avenues for asthma management.
Click here for the full article.
4.) Maternal tobacco use tied to late childhood neurocognition deficits
Compared to children with no maternal tobacco usage during pregnancy, those exposed had associations to childhood neurocognition deficits.
Click here for the full article.
5.) Black youths and females face higher risk for foster care involvement
Results demonstrated that foster care involvement does vary based on age and sex, with Black youths and females disproportionately effected.
